A biologics license application (BLA) has been submitted to the FDA for etentamig (ABBV-383), an investigational BCMA x CD3 ...
AbbVie (ABBV) filed a biologics license application with the US Food and Drug Administration for etentamig, a second-generation BCMA-directed bispecific antibody for adults with relapsed or refractory ...
In the Phase 3 MagnetisMM-32 trial, ELREXFIO demonstrated a clinically meaningful and statistically significant benefit for ...
The Phase 3 trial showed a 60% risk reduction on its progression-free survival measure; dosing began with one step-up dose, ...
4hon MSN
Pfizer posts late-stage trial win for multiple myeloma drug Elrexfio in an earlier line setting
Pfizer (PFE) on Tuesday announced a successful late-stage trial outcome for its multiple myeloma therapy, Elrexfio (elranatamab), when used in an earlier-line setting against the hematological cancer.
CellsBin®, a biotechnology company pioneering Rare-Cell Biology™, today announced that it has received a Direct-to-Phase II Small Business Innovation Research (SBIR) award from the National Cancer ...
Adaptive Biotechnologies gains from new myeloma MRD guidelines, strong clonoSEQ growth, and refinancing tailwinds. Read why ...
AbbVie announced the submission of a Biologics License Application to the U.S. Food and Drug Administration for etentamig, a second-generation BCMA x CD3 bispecific antibody T-cell engager ...
Multiple Myeloma Symptoms, Treatment & Prognosis / blood cancer, Bone Lesions, Cancer in Younger Adults, Cassie ...
The International Myeloma Foundation formed a network aiming to expand access to clinical trials for people with myeloma.
Nearly half of patients with multiple myeloma experience pathological fractures, according to a retrospective analysis of 692 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results